Trulicity
(Dulaglutide)ApprovedPeptide
Eli LillyDulaglutide is used to help people with type 2 diabetes control their blood sugar levels, and it can also help reduce the risk of heart disease in people with diabetes.[2] Trulicity is currently approved and in use across 17 indications[4].[1]
Trulicity is one of 368 small molecule programs targeting Glucose intolerance. It is currently in Approved.
17
Indications
90
Total Trials
15
Active Trials
367
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 16 indications
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Trulicity
Eli LillyApproved
Byetta
AstraZenecaPreclinical
Jardiance
Boehringer IngelheimPreclinical
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes29 trials
Show 26 more trials
Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
Unknown status·—·Phase 4·NCT04893148·40 enrolled
Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
Active, not recruiting·FFundación para la Investigación del Hospital Clínico de Valencia·Phase 4·NCT06851962·504 enrolled
The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.
Unknown status·SSecond Xiangya Hospital of Central South University·Phase 4·NCT05005741·120 enrolled
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Active, not recruiting·—··NCT06779929·70,000 enrolled
Type 2 Diabetes Mellitus16 trials
The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria
Active, not recruiting·—·N/A·NCT06611904·60 enrolled
Show 13 more trials
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
Active, not recruiting·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 3·NCT06235086·632 enrolled
ART4 trials
T2DM3 trials
Diabetes Mellitus2 trials
Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia
Completed·—·Phase 2·NCT07370922·80 enrolled
29 more indications
Type 1 Diabetes2 trials
Semaglutide2 trials
Chronic Kidney Disease2 trials
GLP-12 trials
Hyperglycemia2 trials
MPA2 trials
Cardiovascular2 trials
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data
Completed·—··NCT07088718·44,671 enrolled
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Completed·—··NCT07096063·887,132 enrolled
Bipolar Disorder1 trial
Diabetic Nephropathy1 trial
Metformin1 trial
Steatosis1 trial
Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)
Unknown status·—·Phase 4·NCT03648554·93 enrolled
Type 1 Diabetes Mellitus1 trial
Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus
Enrolling by invitation·—·Phase 1/2·NCT07319286·50 enrolled
Endothelial Function1 trial
Female1 trial
Liraglutide1 trial
Polydipsia1 trial
Efficacy1 trial
Cardiovascular Events1 trial
Alcoholic Fatty Liver Disease1 trial
Regulatory
FDA Approval Timeline[5]
Sep 18, 2014
TRULICITY
BLA BLA125469
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Trulicity drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Dulaglutide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]